Business, energy, technology, markets and global industry news from Business News Today

Eli Lilly and Company

PharmaDeviceNews Eli Lilly and Company
Pharma & Biotech

Why Lilly is betting on peripheral pain biology with the 4E Therapeutics acquisition

Find out how Lilly’s 4E Therapeutics deal could advance non-opioid chronic pain drugs and what risks remain.

Read More
Representative image: A dermatologist examines an eczema flare, reflecting how EBGLYSS and other atopic dermatitis biologics are shifting the treatment conversation toward fewer injections, longer disease control, and lower patient burden.
Features & Analysis

How EBGLYSS shows the eczema market is moving from breakthrough launches to lifecycle strategy

Find out why fewer injections and longer disease control are becoming key battlegrounds in eczema biologics and dermatology care.

Read More
Pharma & Biotech

Why Lilly’s expanded Ebglyss label could reset dosing expectations in atopic dermatitis biologics

Ebglyss gains an every-eight-week FDA maintenance option, raising new questions for atopic dermatitis biologic competition.

Read More
Representative image of a clinical weight-management consultation with an injection pen and progress chart, reflecting Pfizer’s berobenatide Phase 2b data and the growing race to develop monthly GLP-1 obesity treatments.
Pharma & Biotech

Pfizer’s Phase 2b obesity data put monthly GLP-1 dosing back in investor focus

Find out how Pfizer’s berobenatide Phase 2b data could reshape monthly GLP-1 obesity treatment and late-stage trial strategy.

Read More
Pharma & Biotech

Can L’Oréal-backed funding help OliX Pharmaceuticals turn siRNA science into a broader biotech platform?

Find out how OliX Pharmaceuticals’ KRW 110 billion raise could reshape RNAi therapeutics, beauty biotech, and siRNA platform strategy.

Read More
Representative image of pharmaceutical executives and scientists reviewing drug discovery data in a modern research setting, reflecting Eli Lilly and Haisco Pharmaceutical’s multi-program collaboration and the growing role of China-originated innovation in global pharma licensing.
Pharma & Biotech

Can Eli Lilly’s $3bn Haisco deal deepen big pharma’s China drug discovery pipeline?

Eli Lilly’s Haisco deal could be worth over $3 billion. Find out why China-originated drug discovery is becoming harder to ignore.

Read More
Representative image showing a biotech licensing discussion around long-acting GLP-2 therapy, reflecting Lilly and Hanmi Pharm’s sonefpeglutide deal for short bowel syndrome treatment.
Pharma & Biotech

Can Lilly turn Hanmi’s sonefpeglutide into the next long-acting GLP-2 rare disease bet?

Read why Lilly’s Hanmi sonefpeglutide deal could reshape long-acting GLP-2 therapy for short bowel syndrome.

Read More
Representative image of next-generation vaccine research, showing how AAHI’s SLA-SE adjuvant technology is gaining attention through Eli Lilly and Company’s acquisition of Curevo Vaccine and its shingles vaccine candidate amezosvatein.
Pharma & Biotech

Lilly’s Curevo deal turns AAHI’s adjuvant science into a late-stage vaccine opportunity

Find out how AAHI’s SLA-SE adjuvant could shape Lilly’s next-generation shingles vaccine strategy after the Curevo acquisition.

Read More
Representative image: Eli Lilly’s expanding diabetes and obesity drug pipeline, including Foundayo, Mounjaro and retatrutide, highlights the growing race to reshape cardiometabolic care through oral GLP-1 therapies, injectable incretin drugs and next-generation clinical trial advances.
Pharma & Biotech

Can Eli Lilly’s Foundayo and retatrutide deepen its grip on the diabetes and obesity market?

Find out how Eli Lilly’s Foundayo and retatrutide data could reshape diabetes, obesity and cardiometabolic care.

Read More
Pharma & Biotech

How Eli Lilly and Company is positioning VERVE-102 at the center of cardiovascular gene editing

Can Eli Lilly and Company’s VERVE-102 transform cholesterol treatment through one-time gene editing? Explore the risks, data, and implications.

Read More